Evidence map›Paper›PMID 41886485›Full record

ArticlePloS one2026

High-throughput high content quantification of HIV-1 viral infectious output.

Teresa LuPone, Alexis Brantly, Oluwatofunmi Oteju, Stephanie M Matt, Kaitlyn Runner, Emily A Nickoloff-Bybel, Michael R Nonnemacher, Peter J Gaskill

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Teresa LuPoneDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Alexis BrantlyDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0002-8020-2993
Oluwatofunmi OtejuDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Stephanie M MattDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Kaitlyn RunnerDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Emily A Nickoloff-BybelDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Michael R NonnemacherDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0003-4299-3779
Peter J GaskillDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0003-0095-5424

Funding

Benzodiazepine mediated mechanisms of transcriptional semi-quiescence in discrete myeloid populationsR01DA057337 · NIDA · DREXEL UNIVERSITY · PI Peter Jesse Gaskill, Zachary Alan Klase · 2022 to 2026
$3.4M
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIVR33DA058501 · NIDA · DREXEL UNIVERSITY · PI Peter Jesse Gaskill · 2025 to 2026
$1.4M
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIVR61DA058501 · NIDA · DREXEL UNIVERSITY · PI GASKILL, PETER JESSE · 2023 to 2024
$1.1M
NIDA NIH HHS R01 DA057337NIDA NIH HHS R33 DA058501NIDA NIH HHS R61 DA058501
6 · The paper itself

Abstract

Infection with human immunodeficiency virus (HIV-1) remains a global health issue and still drives the development of significant pathology and various comorbidities. Antiretroviral therapy (ART) can effectively suppress viral replication but is often initiated months or years after initial infection, leaving a substantial period in which viral replication progresses unchecked. While ART suppresses HIV-1 replication, it does not prohibit the development of HIV-1-associated comorbidities, highlighting a lack of understanding in the connection between replication and HIV-1-associated pathogeneses. Further, a high percentage of all HIV-1 virions produced are non-infectious, and this proportion is much higher in ART-treated individuals, showing that despite inefficient viral replication, which becomes even less efficient with ART, HIV-1 is still able to drive disease. Thus, it is critical to better define HIV-1 replication dynamics to more effectively target different stages of the viral replication cycle in distinct cell populations. Here, we show a high-content imaging reporter assay that uses modified human osteosarcoma cells expressing HIV-1 receptors (GHOST cells) which fluoresce in response to HIV-1 infection. These cells have been previously used to assess HIV-1 infectivity and tropism, but this modified assay enables rapid evaluation of large numbers of samples with consistency and replicability, while also easily integrating into existing experimental pipelines that analyze p24 secretion in collected supernatants. This also allows for direct correlation between infectivity and p24 secretion, resulting in a deeper interrogation and more robust understanding of HIV-1 infection kinetics.

Indexed as

High-Throughput Screening AssaysHIV-1HIV InfectionsVirus ReplicationCell Line, TumorHumans

Identifiers

PMID41886485
PMCPMC13020823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.